Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
Protagonist Therapeutics (NASDAQ:PTGX) announced that Dinesh V. Patel, Ph.D., President and CEO will present a company overview at the 44th Annual J.P.
Rhea-AI Summary
Protagonist Therapeutics (NASDAQ:PTGX) announced that Dinesh V. Patel, Ph.D., President and CEO will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 8:15 AM PST.
The company will hold one-on-one investor meetings during the conference. A live webcast is available at the provided J.P. Morgan link, and a replay will be posted on Protagonist's Investor Relations Events and Presentations webpage for one year following the event. Investors seeking meetings should contact their J.P. Morgan representative.
Positive
- None.
Negative
- None.
Details
News Market Reaction – PTGX
On Jan 7, the day this news came out, PTGX closed 0.09% above the previous close.
Data tracked by StockTitan Argus for the Jan 7 session.
Key Figures
- Conference dates
- January 12–15, 2026
- 44th Annual J.P. Morgan Healthcare Conference schedule
- Company presentation date
- January 13, 2026
- Scheduled Protagonist presentation day at J.P. Morgan conference
- Presentation time
- 8:15 AM PST
- Slot for company overview webcast
- Current price
- $82.27
- Pre-news close vs 52-week range $33.70–$96.54
- Price change 24h
- -2.27%
- Move ahead of conference participation announcement
- 52-week high discount
- -14.78%
- Distance from 52-week high of $96.54
- 200-day MA
- $62.29
- Shares trading above long-term moving average
- Market cap
- $5,262,568,764
- Equity value prior to conference news
Historical Context
-
NDA filed for rusfertide in PV with positive VERIFY Phase 3 data.
-
Q3 2025 results and broad pipeline milestones with strong cash runway.
-
Multiple rusfertide presentations at ASH highlighting Phase 3 and extension data.
-
New icotrokinra data in UC and psoriasis supporting ongoing ICONIC programs.
-
Phase 2b ANTHEM-UC results showing strong efficacy and favorable safety.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWARK, CA / ACCESS Newswire / January 7, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference taking place January 12-15, 2026 in San Francisco, CA. The Company will also participate in one-on-one meetings.
44th Annual J.P. Morgan Healthcare Conference - January 12-15, 2026
Format: Company Presentation
Day/Time: Tuesday, January 13 at 8:15 AM PST
If you are interested in meeting with the Protagonist team during the conference, please reach out to your J.P. Morgan representative.
A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage for one year following the event.
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with a New Drug Application (NDA) for icotrokinra submitted to the FDA in July, and an NDA for rusfertide submitted in December 2025. Icotrokinra (formerly, JNJ-2113), is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R"), which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Following icotrokinra's joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for the development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of preclinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and the oral hepcidin program.
More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company's website at https://www.protagonist-inc.com.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
Media Contact
Virginia Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com
SOURCE: Protagonist Therapeutics
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.